What does “adding indications during execution” mean in a clinical study?
Adding indications mid-study usually means you are expanding the study’s scope so the same investigational product is evaluated in one or more new disease conditions (or additional labeled-like patient groups) after enrollment has started. This can involve:
- Adding new study objectives (for safety/efficacy in the new indication).
- Modifying eligibility criteria (new disease diagnosis, severity, prior therapy).
- Changing endpoints or assessment schedules.
- Potentially increasing sample size and site workload.
Because indications are tied to regulatory approval and trial authorization, this type of change is typically handled as a protocol amendment and usually triggers updated review by ethics committees/IRBs and regulators, depending on jurisdiction and how large the change is.
When can you add an indication during a trial, and what drives the decision?
Whether you can do it (and how fast) depends on factors like:
- How far the trial is already underway (ongoing enrollment vs. mostly complete).
- Whether the new indication changes patient risk (new populations, comorbidities, dosing assumptions).
- Whether the new indication requires different dosing/regimens, endpoints, or assessment windows.
- Whether it’s truly “new indication” or just a subgroup analysis planned earlier.
Operationally, the earlier in the trial you define the possibility, the easier it is to execute. If the study was not designed for the new indication, you may need new statistical assumptions and additional power to make the new indication results credible.
How is this typically implemented: protocol amendment vs. addendum
In practice, adding indications during execution is almost always done via:
- A protocol amendment (core document change: eligibility, objectives/endpoints, design, sample size, analysis plan).
- Often an amended informed consent, sponsor communications, and investigator training.
Some programs try to avoid “changing indications” after start by designing:
- Adaptive approaches (pre-specified criteria to expand).
- Master protocol designs (e.g., basket/platform concepts) where adding disease cohorts is part of the original design.
If the indication expansion was not pre-planned, regulators and ethics bodies often expect more documentation, and timelines can be longer.
What approvals are usually required (ethics, regulators, and trial registries)?
At minimum, you usually need to update:
- Ethics/IRB documents (protocol, consent forms, investigator brochure references as applicable).
- Regulatory filings/authorizations, where required for protocol changes.
- Clinical trial registration updates (e.g., ClinicalTrials.gov record updates or equivalent in other registries).
If the change is substantial (new indication, new endpoints, meaningful risk), the review and update timelines can become a limiting factor.
Does adding indications change the analysis plan and endpoints?
Often yes. Adding an indication can require:
- A re-forecast of sample size and statistical power for the new indication.
- Separate analysis by indication (and sometimes by line of therapy or biomarker subgroup).
- Clarification of multiplicity control if you are effectively testing multiple indications/endpoints.
- Updated safety monitoring plan tailored to the new patient population.
Even if the underlying mechanism of action is the same, endpoints and event rates can differ greatly between indications, which affects feasibility and interpretability.
What happens to safety reporting and data monitoring?
A new indication can change:
- Expected adverse event profiles.
- Baseline risk and monitoring intensity.
- Stopping rules or escalation rules (if your safety triggers depend on population).
That means oversight bodies (e.g., Data Safety Monitoring Board, pharmacovigilance procedures) may require updates to reflect the new population and risk assumptions.
What are common pitfalls when adding indications mid-execution?
Common problems include:
- Underpowered design for the added indication because sample size assumptions weren’t updated.
- Inconsistent endpoints across cohorts due to operational differences at sites.
- Enrollment delays caused by revised inclusion/exclusion criteria and revised consent language.
- Regulatory/IRB review delays that temporarily stop or slow screening/enrollment.
- Confusion in datasets and analysis because indication was not built into the original randomization stratification or data model.
If you want, share your scenario and I can map the likely change path
To give more specific guidance, tell me:
- Is this a phase 1/2/3 study?
- Is the new indication added to the same protocol or a separate protocol?
- Are dosing/regimen and endpoints staying the same or changing?
- At what stage is the trial (enrollment ongoing, recruitment paused, mostly enrolled)?
- What region(s) are involved (EU/US/UK/etc.)?
With that, I can outline what typically needs to change (protocol sections, approvals, and analysis impacts) for an indication expansion during execution.